MAPT and fragile X syndrome: To further determine whether targeting Tau has therapeutic potential for FXS, we used osmotic pumps to release Tau-targeting ASO (ASO-Tau) and control ASO (ASO-NC) into the lateral ventricles of 1-month-old Fmr1−/y mice with an FVB background for two weeks.